Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > FDA to stress opioids’ risk of overdose, death in new medication safety labels
Health and Wellness

FDA to stress opioids’ risk of overdose, death in new medication safety labels

Last updated: August 1, 2025 7:45 am
Share
FDA to stress opioids’ risk of overdose, death in new medication safety labels
SHARE

The Food and Drug Administration (FDA) has taken a significant step in addressing the risks associated with prescription opioids by implementing new labeling requirements for manufacturers. The updated labels will now include stronger language warning about the dangers of higher doses and prolonged use of these medications, emphasizing the potential for overdose and even death.

This decision follows a meeting held by FDA advisory committees to review the findings of two postmarket studies on opioids, which aimed to quantify the risks of long-term opioid use. The move comes after years of scrutiny surrounding the role of opioids in fueling the ongoing epidemic in the United States. Purdue Pharma’s OxyContin, in particular, has been at the center of controversy due to its aggressive marketing tactics and oversupply, which contributed to the initial wave of the crisis.

FDA Commissioner Marty Makary expressed the urgency of addressing the opioid epidemic, acknowledging the devastating toll it has taken on nearly one million Americans. Makary emphasized that the labeling changes are just one part of a broader effort to prevent similar tragedies in the future. The FDA is also urging healthcare providers to prioritize immediate-release opioid products over extended-release options like OxyContin, reserving the latter for cases of severe and persistent pain that cannot be managed with alternative treatments.

One notable addition to the new labeling standards is the requirement for drug manufacturers to warn about the risks associated with rapidly reducing or discontinuing opioid treatment, which can lead to withdrawal symptoms, increased pain, and even suicidal thoughts. This measure aims to prevent patients from experiencing unnecessary harm when transitioning away from opioid therapy.

See also  The unicorn killer: Why regulatory risk keeps destroying startup value and what to do about it

In light of the opioid crisis, some healthcare providers have become more cautious in prescribing opioids, while others have faced challenges in managing existing prescriptions. Abruptly discontinuing opioid treatment can have unintended consequences, such as driving individuals to seek illicit opioids like fentanyl. The FDA’s emphasis on proper tapering and discontinuation strategies is crucial in mitigating these risks.

Additionally, the updated labels will now include information on medications like naloxone, which can reverse opioid overdose. By raising awareness about overdose reversal options, the FDA hopes to empower both patients and healthcare providers to take proactive steps in preventing fatal outcomes.

While the full impact of the FDA’s labeling changes remains to be seen, the agency’s efforts align with broader trends in opioid prescribing practices. Annual opioid prescriptions in the U.S. have declined significantly in response to the epidemic and increased scrutiny over prescribing practices. Deaths involving prescription opioids, excluding illicit substances like heroin or fentanyl, have shown a consistent decrease since reaching a peak in 2011.

In a recent interview, Commissioner Makary reflected on the need for accurate and science-based labeling for opioids, citing his own experiences as a prescriber. The FDA’s decision to remove misleading language like “extended treatment period” from opioid labels underscores the importance of evidence-based prescribing practices.

The American Medical Association (AMA) has expressed support for the FDA’s actions, emphasizing the importance of shared decision-making between patients and healthcare providers in opioid therapy. The organization underscores the need for a cautious approach to opioid prescribing, starting with low doses and proceeding carefully to minimize the risk of harm to patients.

See also  How Preschool Can Boost Your Child’s Mental Health

Overall, the FDA’s efforts to enhance opioid labeling represent a critical step in addressing the ongoing opioid epidemic and promoting safe prescribing practices. By emphasizing the risks associated with long-term opioid use and providing clear guidance on tapering and discontinuation, the agency aims to protect patients and prevent further harm in the future.

TAGGED:deathFDALabelsMedicationopioidsoverdoseRiskSafetystress
Share This Article
Twitter Email Copy Link Print
Previous Article Seth Meyers Gobsmacked By Trump’s Latest Brain Blip: ‘Oh Dude, Don’t Admit That!’ Seth Meyers Gobsmacked By Trump’s Latest Brain Blip: ‘Oh Dude, Don’t Admit That!’
Next Article Nightfall launches ‘Nyx,’ an AI that automates data loss prevention at enterprise scale Nightfall launches ‘Nyx,’ an AI that automates data loss prevention at enterprise scale
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Jeff Bezos and Lauren Sanchez Saddle Up in Aspen, Shop for Cowboy Hats

Jeff Bezos and Lauren Sanchez were spotted enjoying the winter wonderland of Aspen over the…

December 29, 2024

Samsung Galaxy Z Flip 7 Review: Hands-on

The Galaxy Z Flip series has always been a point of intrigue for tech enthusiasts,…

July 9, 2025

Top 10 Sporting Events To Experience In 2025

2025 is set to be a spectacular year for sports enthusiasts around the world. From…

June 1, 2025

Diddy Prosecutors Working on Superseding Indictment After New Evidence Emerges

Sean 'Diddy' Combs to Face Expanded Indictment with New Evidence Sean 'Diddy' Combs is set…

October 3, 2024

John Cena’s impressive streak continues following WWE Night of Champions 2025

Undisputed WWE Champion John Cena continues to dominate in the ring, with his last trip…

June 29, 2025

You Might Also Like

Reba McEntire Supports Dolly Parton After She Calls Out Death Hoax
Entertainment

Reba McEntire Supports Dolly Parton After She Calls Out Death Hoax

October 10, 2025
Woke Hollywood is Dying a Slow Death as Jobs Evaporate: ‘Decline Shows No Signs of Stopping’ | The Gateway Pundit | by Mike LaChance
Politics

Woke Hollywood is Dying a Slow Death as Jobs Evaporate: ‘Decline Shows No Signs of Stopping’ | The Gateway Pundit | by Mike LaChance

October 10, 2025
Adidas to Enter Safety Footwear in 2026 With New ‘Pro Work’ Line
Economy

Adidas to Enter Safety Footwear in 2026 With New ‘Pro Work’ Line

October 10, 2025
President Trump is in ‘exceptional health,’ his doctor says, after visit to Walter Reed
Health and Wellness

President Trump is in ‘exceptional health,’ his doctor says, after visit to Walter Reed

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?